1920 S Arkansas St
Springhill, LA
Louisiana COVID-19 Cases
Louisiana New Coronavirus Cases:
Louisiana Total Coronavirus Cases: 1,606,064
Louisiana New Coronavirus Deaths:
Louisiana Total Coronavirus Deaths: 19,005
Louisiana Total Coronavirus Cases: 1,606,064
Louisiana New Coronavirus Deaths:
Louisiana Total Coronavirus Deaths: 19,005
U.S. New Coronavirus Cases: 1,648
U.S. Total Coronavirus Cases: 107,184,620
U.S. New Coronavirus Deaths: 8
U.S. Total Coronavirus Deaths: 1,166,662
U.S. Total Coronavirus Cases: 107,184,620
U.S. New Coronavirus Deaths: 8
U.S. Total Coronavirus Deaths: 1,166,662
Last updated June 10, 2023
Sarepta and other towns across Louisiana are putting proactive measures in place to quell the spread of COVID-19. Disruptions to school, work, and major public gatherings are already manifesting and it’s important to stay up to date on what’s happening in the Sarepta, LA community.
Stay up to date and informed with our resources: Breaking public health news, information on your local Louisiana hospitals and healthcare facilities, information from the Louisiana Public Health Department, and Twitter updates from Louisiana government officials. Continue to visit our website for the latest updates.
Coronavirus News for Sarepta
Sarepta Faces Investor Skepticism As Duchenne Data Falls Short Of Statistical Significance
Sarepta's Duchenne trial missed its main goal but showed trends favoring treatment; Q3 earnings topped estimates amid Elevidys sales weakness. More info »
Benzinga - 11/04/2025 02:33amSarepta slumps as trial failure deepens woes for drugmaker
Sarepta Therapeutics' shares plunged nearly 40% in premarket trading on Tuesday as failure of two of its approved drugs for a muscle wasting disorder in a key trial raised concerns about the strength ... More info »
Reuters on MSN - 11/03/2025 10:22pmSarepta Stock’s (SRPT) Painful Plunge! Is There Any Hope Left for Investors after DMD Trial Miss?
Shares of Sarepta Therapeutics ($SRPT) plunged after the company reported disappointing results from a key trial of its Duchenne muscular ... More info »
TipRanks on MSN - 11/04/2025 04:43amSarepta's shares plunge after trial for muscle-wasting disease drugs miss key goal
Sarepta said on Monday that its late-stage study testing two gene-targeted therapies for Duchenne muscular dystrophy did not meet the main goal, sending its shares plummeting over 37% in extended ... More info »
Reuters on MSN - 11/03/2025 09:40am
